Clinical Trials Logo
  1. Home
  2. Coronavirus Infections
  3. NCT04414631

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Coronavirus Infections Clinical Trial

Official title:
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).

Clinical Trial Summary

The aim of this study is to analyze if administration of conestat alfa for 72 hours in addition to standard of care (SOC) in patients hospitalized with non-critical SARS-CoV-2 pneumonia (WHO Ordinal Scale Score 3 or 4) reduces the risk of disease progression to Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).

Clinical Trial Description

Systemic hyperinflammation is a hallmark of more severe stages of COVID-19 leading to acute respiratory distress syndrome, mechanical ventilation and ultimately death. In this stage, COVID-19 is associated with a decrease in suppressor and regulatory T cell counts and an extensive release of proinflammatory cytokines and biomarkers called a cytokine storm, which is thought to be the major driver of severe pneumonia caused by SARS-CoV-2. C1 esterase inhibitor (C1INH) is a member of the serpin superfamily of serine-protease inhibitors and is a strong inhibitor of the complement System (CS) and the kinin-kallikrein (KK) System. Conestat alfa is a recombinant human C1INH, that shares an identical protein structure with plasma-derived C1INH. The rationale of the current trial is based upon the following assumptions: In the context of COVID-19, conestat alfa treatment may 1) dampen uncontrolled complement activation and collateral lung damage and 2) reduce capillary leakage and subsequent pulmonary edema by direct inhibition of KK system. The aim of this study is to analyze administration of conestat alfa for 72 hours in addition to standard of care in patients hospitalized with non-critical SARS-CoV-2 pneumonia (WHO Ordinal Scale Score 3 or 4) and its association with clinical severity on day 7 after inclusion and the risk of disease progression to Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04414631
Study type Interventional
Source University Hospital, Basel, Switzerland
Contact
Status Terminated
Phase Phase 2
Start date August 6, 2020
Completion date September 15, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04553575 - CoViD-19 Patient in Reims University Hospital in March to April 2020
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Active, not recruiting NCT05548439 - Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a Phase 1
Completed NCT05046548 - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Phase 1/Phase 2
Active, not recruiting NCT05726084 - Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older Phase 2/Phase 3
Recruiting NCT05069129 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 1/Phase 2
Enrolling by invitation NCT05054075 - Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Phase 2
Recruiting NCT05599516 - Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial Phase 3
Completed NCT05047900 - The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community N/A
Completed NCT04420286 - Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
Completed NCT04424355 - Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Terminated NCT04409873 - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Phase 2
Enrolling by invitation NCT04327349 - Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial N/A
Completed NCT04321278 - Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) Phase 3
Recruiting NCT04327570 - In-depth Immunological Investigation of COVID-19.
Completed NCT04326309 - Audio Data Collection for Identification and Classification of Coughing
Recruiting NCT04322344 - Escin in Patients With Covid-19 Infection Phase 2/Phase 3
Completed NCT04323592 - Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
Completed NCT04328129 - Household Transmission Investigation Study for COVID-19 in Tropical Regions N/A